| Paper | Authors | Journal | Year | Type |
|---|
| Effect of neoadjuvant androgen deprivation therapy on prostate and tumor morphology prior to MRI-guided transurethral ultrasound ablation of prostate cancer | Virtanen I et al. | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group | 2026 | Clinical Trial, Phase I |
| Resting state functional connectivity in paedophilic disorder and degarelix treatment | Andersson L et al. | Acta neuropsychiatrica | 2026 | Randomized Controlled Trial |
| Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer | Jarrard D et al. | Journal for immunotherapy of cancer | 2026 | Randomized Controlled Trial |
| Final Results of the Randomised Phase 2 Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer (ARNEO) | Giesen A et al. | European urology oncology | 2026 | Randomized Controlled Trial |
| Relationship between [(18)F]PSMA-1007 PET parameters and biochemical recurrence-free survival in high-risk prostate cancer patients receiving neoadjuvant hormonal treatment | Ahmadi Bidakhvidi N et al. | European journal of nuclear medicine and molecular imaging | 2026 | Randomized Controlled Trial |
| Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial | Zilli T et al. | European urology oncology | 2025 | Randomized Controlled Trial |
| Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer | Dev H et al. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | Randomized Controlled Trial |
| Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial | Parker CC et al. | Lancet (London, England) | 2024 | Randomized Controlled Trial |
| Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial | Parker CC et al. | Lancet (London, England) | 2024 | Randomized Controlled Trial |
| Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study | Bergamini M et al. | eLife | 2024 | Clinical Trial, Phase IV |
| Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer | Spratt DE et al. | JAMA oncology | 2024 | Randomized Controlled Trial |
| Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study | Mytilekas VK et al. | Investigative and clinical urology | 2023 | Randomized Controlled Trial |
| Changes in bone and mineral homeostasis after short-term androgen deprivation therapy with or without androgen receptor signalling inhibitor - substudy of a single-centre, double blind, randomised, placebo-controlled phase 2 trial | David K et al. | EBioMedicine | 2023 | Randomized Controlled Trial |
| A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer | De La Cerda J et al. | Targeted oncology | 2023 | Clinical Trial, Phase I |
| Comparison of Quality of Life and Injection Site Reactions After Switching from Degarelix [amount hidden] to [amount hidden] in Advanced Prostate Cancer: A Prospective Trial | Miyajima K et al. | Anticancer research | 2023 | Clinical Trial |
| ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer | Devos G et al. | European urology | 2023 | Randomized Controlled Trial |
| Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial | Nickols NG et al. | JAMA network open | 2022 | Randomized Controlled Trial |
| Effects of testosterone suppression on desire, hypersexuality, and sexual interest in children in men with pedophilic disorder | Landgren V et al. | The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry | 2022 | Randomized Controlled Trial |
| Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy | Sasaki H et al. | Andrology | 2022 | Randomized Controlled Trial |
| Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial | Lopes RD et al. | Circulation | 2021 | Randomized Controlled Trial |
| Loss of SNAI2 in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy | Cmero M et al. | JCO precision oncology | 2021 | Clinical Trial, Phase II |
| Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study | Palumbo C et al. | Prostate cancer and prostatic diseases | 2021 | Clinical Trial, Phase IV |
| Degarelix as a neoadjuvant hormonal therapy for acute urinary tract toxicity associated with external beam radiotherapy for intermediate- and high-risk prostate cancer: a propensity score matched analysis | Hata S et al. | Japanese journal of clinical oncology | 2021 | Clinical Trial |
| Effect of Gonadotropin-Releasing Hormone Antagonist on Risk of Committing Child Sexual Abuse in Men With Pedophilic Disorder: A Randomized Clinical Trial | Landgren V et al. | JAMA psychiatry | 2020 | Randomized Controlled Trial |
| The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial | Dearnaley DP et al. | European urology | 2020 | Randomized Controlled Trial |
| Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with (68)Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer | Ettala O et al. | European journal of nuclear medicine and molecular imaging | 2020 | Clinical Trial |
| Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study | Sawazaki H et al. | World journal of urology | 2020 | Randomized Controlled Trial |
| Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial | Dellapasqua S et al. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019 | Randomized Controlled Trial |
| FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist | Crawford ED et al. | Scandinavian journal of urology | 2018 | Randomized Controlled Trial |
| Aromatized Estrogens Amplify Nocturnal Growth Hormone Secretion in Testosterone-Replaced Older Hypogonadal Men | Roelfsema F et al. | The Journal of clinical endocrinology and metabolism | 2018 | Randomized Controlled Trial |